Emeramide

Drug Profile

Emeramide

Alternative Names: Irminix; NBMI; OSR#l

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator University of Kentucky
  • Developer EmeraMed Limited
  • Class Benzene derivatives; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Antioxidants; Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Heavy metal poisoning
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Heavy metal poisoning

Most Recent Events

  • 05 Jul 2016 Phase-II clinical trials in Chronic obstructive pulmonary disease in Sweden (PO) (EudraCT2016-001805-18)
  • 23 Jan 2016 EmeraMed Limited completes enrolment in its phase IIa trial for Heavy metal poisoning in Ecuador
  • 31 Aug 2015 Phase-IIa clinical trials in Heavy metal poisoning in Ecuador (PO) (NCT02486289)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top